Lori M. Minasian

22.2k total citations · 2 hit papers
201 papers, 9.9k citations indexed

About

Lori M. Minasian is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Economics and Econometrics. According to data from OpenAlex, Lori M. Minasian has authored 201 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 42 papers in Public Health, Environmental and Occupational Health and 42 papers in Economics and Econometrics. Recurrent topics in Lori M. Minasian's work include Health Systems, Economic Evaluations, Quality of Life (36 papers), Ovarian cancer diagnosis and treatment (32 papers) and Ethics in Clinical Research (28 papers). Lori M. Minasian is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (36 papers), Ovarian cancer diagnosis and treatment (32 papers) and Ethics in Clinical Research (28 papers). Lori M. Minasian collaborates with scholars based in United States, Canada and Malaysia. Lori M. Minasian's co-authors include Ian M. Thompson, Catherine M. Tangen, Phyllis J. Goodman, Howard L. Parnes, Leslie G. Ford, Scott M. Lippman, Joseph M. Unger, M. Scott Lucia, Elise C. Kohn and Dawn L. Hershman and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Lori M. Minasian

193 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

2004 1.7k citations Ian M. Thompson, Phyllis J. Goodman et al. profile →
Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

2018 343 citations Joseph M. Unger, Riha Vaidya et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lori M. Minasian United States	49	3.6k	2.8k	2.0k	1.5k	1.2k	201	9.9k
Mats Lambe Sweden	62	4.9k 1.4×	2.5k 0.9×	1.4k 0.7×	1.3k 0.9×	1.5k 1.2×	293	12.0k
Martin R. Stockler Australia	50	4.4k 1.2×	3.8k 1.4×	1.1k 0.6×	1.1k 0.8×	1.5k 1.3×	374	10.0k
Paul W. Dickman Sweden	59	4.0k 1.1×	1.8k 0.6×	1.2k 0.6×	1.4k 1.0×	959 0.8×	198	12.5k
Eva Steliarova‐Foucher France	26	3.8k 1.1×	2.2k 0.8×	1.9k 1.0×	1.6k 1.1×	1.2k 1.0×	54	9.3k
Betsy Kohler United States	30	6.2k 1.7×	2.9k 1.0×	2.6k 1.3×	1.4k 1.0×	2.0k 1.6×	61	13.9k
Hannah K. Weir United States	38	3.9k 1.1×	1.9k 0.7×	1.4k 0.7×	603 0.4×	1.1k 0.9×	84	8.1k
Michel P. Coleman United Kingdom	61	6.7k 1.9×	2.2k 0.8×	1.3k 0.7×	1.4k 1.0×	1.2k 1.0×	291	13.3k
Isabel dos‐Santos‐Silva United Kingdom	47	4.1k 1.2×	2.4k 0.8×	1.1k 0.6×	1.4k 1.0×	1.4k 1.2×	155	9.4k
Aminah Jatoi United States	50	4.6k 1.3×	2.6k 0.9×	2.4k 1.2×	1.1k 0.8×	842 0.7×	400	13.6k
Otis W. Brawley United States	34	5.1k 1.4×	3.6k 1.3×	2.3k 1.2×	895 0.6×	1.8k 1.5×	61	11.5k

Countries citing papers authored by Lori M. Minasian

Since Specialization

Citations

This map shows the geographic impact of Lori M. Minasian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori M. Minasian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori M. Minasian more than expected).

Fields of papers citing papers by Lori M. Minasian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori M. Minasian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori M. Minasian. The network helps show where Lori M. Minasian may publish in the future.

Co-authorship network of co-authors of Lori M. Minasian

This figure shows the co-authorship network connecting the top 25 collaborators of Lori M. Minasian. A scholar is included among the top collaborators of Lori M. Minasian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori M. Minasian. Lori M. Minasian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Skarlupka, Amanda L., Christos Patriotis, Wendy S. Rubinstein, et al.. (2025). Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute’s Vanguard Study. Cancer Epidemiology Biomarkers & Prevention. 34(10). 1787–1793.

Minasian, Lori M., et al.. (2025). Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023). JNCI Cancer Spectrum. 9(3). 1 indexed citations

Samimi, Goli, Sarah M. Temkin, Carol J. Weil, et al.. (2024). Primary care physicians and laypersons’ perceptions of multicancer detection clinical trial designs. JNCI Cancer Spectrum. 8(5).

Unger, Joseph M., Cathee Till, Catherine M. Tangen, et al.. (2024). Long-Term Adverse Effects and Complications After Prostate Cancer Treatment. JAMA Oncology. 10(12). 1654–1654. 9 indexed citations

Rubinstein, Wendy S., Christos Patriotis, Anthony Dickherber, et al.. (2024). Cancer screening with multicancer detection tests: A translational science review. CA A Cancer Journal for Clinicians. 74(4). 368–382. 34 indexed citations

Minasian, Lori M., Paul F. Pinsky, Hormuzd A. Katki, et al.. (2022). Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. JNCI Journal of the National Cancer Institute. 115(3). 250–257. 36 indexed citations

Samimi, Goli, et al.. (2022). Report from an NCI Roundtable: Cancer Prevention in Primary Care. Cancer Prevention Research. 15(5). 273–278. 3 indexed citations

Unger, Joseph M., Dawn L. Hershman, Cathee Till, et al.. (2020). “When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. JNCI Journal of the National Cancer Institute. 113(3). 244–257. 152 indexed citations

Samimi, Goli, Brandy M. Heckman‐Stoddard, Christine Holmberg, et al.. (2020). Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians. Cancer Prevention Research. 14(2). 205–214. 8 indexed citations

10.

Pinsky, Paul F., Eric A. Miller, Brandy M. Heckman‐Stoddard, & Lori M. Minasian. (2019). Breast Cancer Characteristics and Survival among Users versus Nonusers of Raloxifene. Cancer Prevention Research. 13(1). 83–90. 10 indexed citations

11.

Crew, Katherine D., Garnet L. Anderson, Dawn L. Hershman, et al.. (2019). Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prevention Research. 12(7). 481–490. 16 indexed citations

12.

Minasian, Lori M., A. Lindsay Frazier, Lillian Sung, et al.. (2018). Prevention of cisplatin‐induced hearing loss in children: Informing the design of future clinical trials. Cancer Medicine. 7(7). 2951–2959. 15 indexed citations

13.

Shen, Sherry, Joseph M. Unger, Katherine D. Crew, et al.. (2018). Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Research and Treatment. 172(3). 603–610. 33 indexed citations

14.

Lee, Jung Min, Cody J. Peer, Minshu Yu, et al.. (2016). Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clinical Cancer Research. 23(6). 1397–1406. 47 indexed citations

15.

Lubet, Ronald A., James M. Scheiman, Ann M. Bode, et al.. (2015). Prevention of Chemically Induced Urinary Bladder Cancers by Naproxen: Protocols to Reduce Gastric Toxicity in Humans Do Not Alter Preventive Efficacy. Cancer Prevention Research. 8(4). 296–302. 13 indexed citations

16.

Hershman, Dawn L., Joseph M. Unger, Katherine D. Crew, et al.. (2013). Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. Journal of Clinical Oncology. 31(20). 2627–2633. 145 indexed citations

17.

Hay, Jennifer L., Thomas M. Atkinson, Bryce B. Reeve, et al.. (2013). Cognitive interviewing of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Quality of Life Research. 23(1). 257–269. 121 indexed citations

18.

Lee, Jung Min, John L. Hays, Anne M. Noonan, et al.. (2012). Feasibility and safety of sequential research‐related tumor core biopsies in clinical trials. Cancer. 119(7). 1357–1364. 23 indexed citations

19.

Marshall, James R., Catherine M. Tangen, Wael Sakr, et al.. (2011). Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917. Cancer Prevention Research. 4(11). 1761–1769. 83 indexed citations

20.

Annunziata, Christina M., Amanda J. Walker, Lori M. Minasian, et al.. (2010). Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2. Clinical Cancer Research. 16(2). 664–672. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact